Calton & Associates, Inc. Cel Sci Corp Transaction History

Calton & Associates, Inc.

$250 Million
Q3 2024

A detailed history of Calton & Associates, Inc. transactions in Cel Sci Corp stock. As of the latest transaction made, Calton & Associates, Inc. holds 47,140 shares of CVM stock, worth $29,226. This represents 0.02% of its overall portfolio holdings.

Number of Shares

47,140

Previous 31,943 47.58%

Holding current value

$29,226

Previous $33,000 48.48%

% of portfolio

0.02%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$1.05 - $1.5 $15,956 - $22,795	15,197 Added 47.58%	47,140 $49,000
Q3 2024 Oct 18, 2024	BUY	$1.05 - $1.5 $33,540 - $47,914	31,943 New	31,943 $33,000
Q3 2023 Nov 01, 2023	BUY	$1.17 - $2.86 $22,581 - $55,198	19,300 New	19,300 $24,000
Q2 2022 Jul 12, 2022	SELL	$2.58 - $4.99 $1,032 - $1,996	-400 Reduced 2.35%	16,600 $74,000
Q1 2022 Apr 12, 2022	SELL	$3.93 - $7.7 $16,113 - $31,570	-4,100 Reduced 19.43%	17,000 $66,000
Q4 2021 Jan 13, 2022	SELL	$7.1 - $12.82 $35,500 - $64,100	-5,000 Reduced 19.16%	21,100 $149,000
Q3 2021 Nov 05, 2021	SELL	$7.64 - $12.49 $15,280 - $24,980	-2,000 Reduced 7.12%	26,100 $286,000
Q1 2021 May 03, 2021	SELL	$12.0 - $27.64 $40,800 - $93,976	-3,400 Reduced 10.79%	28,100 $427,000
Q4 2020 Jan 25, 2021	BUY	$11.05 - $16.62 $4,420 - $6,648	400 Added 1.29%	31,500 $367,000
Q3 2020 Oct 30, 2020	SELL	$11.69 - $14.54 $4,676 - $5,816	-400 Reduced 1.27%	31,100 $397,000
Q1 2020 Apr 30, 2020	BUY	$7.54 - $17.05 $42,978 - $97,185	5,700 Added 22.09%	31,500 $364,000
Q4 2019 Feb 03, 2020	BUY	$6.71 - $9.55 $173,118 - $246,390	25,800 New	25,800 $236,000
Q1 2018 Apr 17, 2018	SELL	$1.38 - $2.33 $276 - $466	-200 Closed	0 $0
Q4 2017 Feb 05, 2018	BUY	$1.63 - $2.0 $326 - $400	200	200 $0

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Calton & Associates, Inc. with notifications on news.

Account

Calton & Associates, Inc. Cel Sci Corp Transaction History